Northern Star Resources Ltd

NST Details
·         Joint venture with Blackrock Metals:Northern Star Resources Ltd (ASX: NST) stock lost over 4.5% on May 19, 2017 owing to gold price retreat. On the other hand, the group made a Joint Venture with Blackrock Metals to conduct a scoping study to jointly develop Artemis’s Mt Clement-Paulsens gold and silver project. Mt Clement-Paulsens hosts a JORC (2004) compliant Inferred Mineral Resource of 1Mt at 1.7 g/t gold and 17 grams per tonne silver for contained 64,400 ounces of gold and 618,500 ounces of silver. Test work results showed strong results with better than 90% gold recovery.

·         Recommendation: NST stock already rallied over 28.6% in the last six months (as at May 18, 2017); and given the volatile gold prices sentiment, we give an “Expensive” recommendation on the stock at the current price of $ 4.42
 

Mt Clement-Paulsens project location (Source: Company reports)  

Impedimed Ltd

IPD Details
·         Favorable L-Dex Study results:Impedimed Ltd (ASX: IPD) stock corrected over 2.7% on May 19, 2017, apparently owing to some profit booking while the group had delivered outstanding returns a day before. The stock generated over 35% on May 18, 2017 at the back of positive trial results. The group undertook a six-year, 596 patient study in Nashville Breast Center in Nashville, Tennessee which is a major L-Dex study published till date. Over 596 patients using L-Dex showed potential monitoring and intervention result in extremely low rates (3%) of chronic, clinically major breast cancer related lymphedema. This result shows recent guidelines that support prospective screening and intervention for breast cancer related lymphoedema (BCRL).

·         Recommendation:IPD stock lost over 26.8% in this year to date (as of May 18, 2017). There may be more potential to be demonstrated by the group while we give an “Expensive” recommendation on the stock at the current price of $ 0.73

Auscann Group Holdings Ltd

AC8 Details
·         Boosting capital position:Auscann Group Holdings Ltd (ASX: AC8) stock lost over 0.9% on May 19, 2017 post some initial gains. The group raised $12 million from new institutional investors (issuance of 24,000,000 shares at 50 cents a share is expected soon and represents a 16% discount to the five-day volume weighted average price of 59.6 cents per share). The group intends to use these funds for development of cultivation and manufacturing activities, and accelerating its medical outreach programme.

·         Recommendation: AC8 stock rallied over 176.2% in the last three months (as of May 18, 2017) and we believe the momentum to continue. We give a “Hold” recommendation on the stock at the current price of $ 0.57

Disclaimer
 
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated pages are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd currently hold positions in:  BHP, BKY, KCN, PDN, and RIO. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.